Late puberty is defined as the lack of pubertal development at two standard deviations above the mean age for the general population of the geographical area. In practical terms, this is a chronological age of 14 years for males (testicular volume <4 ml) and 13 years for girls (lack of thelarche). The goal of the assessment is to determine whether the delay or lack of development is due to a lag in normal pubertal maturation or represents an abnormality that must be investigated. Etiologies of pubertal delay and pubertal failure include: a) Constitutional delay of puberty (healthy patients with a clinical history of delayed growth and development; b) Hypogonadotropic states (congenital abnormalities, tumours, endocrinopathies); c) Hypergonadotropic states (chromosomal alterations, syndromes, genetic disorders, radiotherapy/chemotherapy); d) Secondary to chronic illness (organic abnormalities, oncological diseases, malnutrition, eating disorders and endocrinopathies). Diagnostic evaluation must include: a detailed physical examination, including auxological parameters (height and bone maturation), personal and familial antecedents, measurements of general hematological and biochemical parameters, gonadotropins, prolactin, thyroid hormones, sex steroids, growth hormone and growth factors. When necessary, an MRI must be performed. A karyotype is indicated in girls with delayed puberty and short stature and in boys who have small testes and hypergonadotropism.

1.
Styne DM: New aspects in the diagnosis and treatment of pubertal disorders. Pediatr Clin North Am 1997;44:505–529.
2.
Pozo J, Argente J: Retraso constitucional del crecimiento y de la adolescencia. Endocrinología 1994;41:60–68.
3.
Cara JF, Rosenfield RL: Insulin-like growth factor I and insulin potentiate luteinizing hormone-induce androgen synthesis by rat ovarian theca-interstitial cells. Endocrinology 1988;123:733–739.
4.
Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Saggese G: Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998;83:4280–4283.
5.
Moreira-Andrés MN, Cañizo FJ, de la Cruz FJ, Gómez de la Cámara A, Hawkins FG: Bone mineral status in prepubertal children with constitutional delay of growth and puberty. J Clin Endocrinol Metab 1998;139:271–275.
6.
Saenger P, Sandberg DE: Delayed puberty: when to wake the bugler. J Pediatr 1998;133:724–726.
7.
Rodríguez-Hierro F: Pubertad retrasada; in Argente J, Carrascosa A, Gracia R, Rodríguez-Hierro F (eds): Tratado de Endocrinología Pediátrica y de la Adolescencia. Madrid, Edimsa, 1995, pp 713–730.
8.
Oberger E, Engström I, Karlberg J: Long-term treatment with glucocorticoids/ACTH in asthmatic children. III. Effects on growth and adult height. Acta Pædiatr Scand 1990;79:77–83.
9.
Preece MA, Low CM, Davies PSW: The growth of children with chronic pediatric diseases. Clin Endocrinol Metab 1986;15:453–477.
10.
Booth IW: Nutritional consequences of gastrointestinal disease in adolescence. Acta Pædiatr Scand 1991;373:91–102.
11.
Handelsman DJ, Dong Q: Hypothalamic-pituitary-gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 1993;22:145–161.
12.
Hokken AC, van Doorn JW, Hahlen K, Stijnen T, de Muinck SM, Drop SL: Long-term effects of treatment for acute lymphoblastic leukemia with and without cranial irradiation on growth and puberty: a comparative study. Pediatr Res 1993;33:577–582.
13.
Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C, Naselli A, Masera G, Terzoli S, Gabutti Y: Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150–155.
14.
Muñoz MT, Morandé G, Argente J: Anomalías en el patrón de secreción de gonadotrofinas en las pacientes afectas de anorexia nervosa. Endocrinología 1997;44:248–252.
15.
Warrem MP: The effect of exercise in pubertal progression and reproductive functions in girls. J Clin Endocrinol Metab 1980;51:1150–1157.
16.
Hardelin JP, Levilliers J, Young J, Pholsena M, Legouis R, Kirk J, Bouloux P, Petit C, Schaison G: Xp22.3 deletions in isolated familial Kallmann’s syndrome. J Clin Endocrinol Metab 1993;76:827–831.
17.
Burris TP, Guo W, McCabe ERB: The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Recent Prog Horm Res 1996;51:241–260.
18.
Zachmann M, Fuchs E, Prader A: Progressive high frequency hearing loss – an additional feature in the syndrome of congenital adrenal hypoplasia and gonadotrophin deficiency. Eur J Pediatr 1992;151:167–169.
19.
Layman LC, Lee EJ, Peak DB, Nammoum AB, Vu KV, van Lingen NL, Gray MR, McDonough PG, Reindollar RH, Jameson JL: Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. N Engl J Med 1997;337:607–611.
20.
Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL: Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 1992;326:179–183.
21.
Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O’Connell SM, Flynn SE, Brown MR, Mullis PE, Parks JS, Phillips JA: Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998;18:147–149.
22.
Dattani MT, Martínez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Martensson IL, Toresson H, Fox M, Wales JK, Hindmarsh PC, Krauss S, Beddington RS, Robinson IC: Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19:125–133.
23.
Kirkilionis A, Gregory CA, Hamerton JL: Long-range restriction mapping and linkage analysis of the Prader-Willi chromosome region (PWCR). Genomics 1991;9:524–535.
24.
Banna M, Hoare RD, Stanley P: Craniopharyngioma in children. J Pediatr 1973;83:781–785.
25.
Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, Conte FA: Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab 1997;82:1362–1367.
26.
Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG: Langerhans cell histiocytosis (histiocytosis X) – a clonal proliferative disease. N Engl J Med 1994;331:154–160.
27.
Richards GE, Wara WM, Grumbach MM, Kaplan SL, Sheline GE, Conte FA: Delayed onset of hypopituitarism: sequelae of therapeutic irradiation of central nervous system, eye and middle ear tumors. J Pediatr 1976;89:553–559.
28.
Rosenfeld RG, Grumbach MM: Turner Syndrome. New York, Marcel Dekker, 1990.
29.
Latronico AC, Anasti J, Arnhold IJP, Rapaport R, Mendonca BB, Bloise W, Castro M, Tsigos C, Chrousos GP: Brief report: testicular and ovarian resistance to luteinizing hormone caused by homozygous inactivating mutations of the luteinizing hormone receptor gene. N Engl J Med 1996;334:507–512.
30.
Aitomaki K, Herva R, Stennman U-H, Juntunen K, Ylostato P, Hovatta O, Chapelle A: Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 1996;81:3722–3726.
31.
Jasmieson CR, van der Burgt I, Brady AF, van Reen M, Elsawi MM, Hol F, Jeffery S, Patton MA, Mariman E: Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat Genet 1994;8:357–360.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.